Ubiquigent and Debiopharm enter into agreement to support USP1 inhibitor program for Debio 0432

Ubiquigent and Debiopharm enter into agreement to support USP1 inhibitor program for Debio 0432

Ubiquigent Limited (Ubiquigent), a drug discovery and development company leveraging novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Debiopharm, a biopharmaceutical company to develop tomorrow's standard-of-care treatments to cure cancer and infectious diseases. The agreement will support the development of Debiopharm's USP1 inhibitor program, Debio 0432.

Under the agreement, Ubiquigent will leverage its DUB-focused platform, combined with its deep understanding of the DUB space, to develop novel target engagement assays to support Debio-0432 on its path to clinical development.

Currently in late-stage preclinical development, Debio 0432 is a small molecule with first-in-class potential that could be used to target multiple tumor types. Through its potent and selective inhibition of USP1, a critical player in the DNA damage repair (DDR) pathway, Debio 0432 has the potential to induce synthetic lethality in tumor types with underlying defects in DNA repair genes.

We are pleased to enter into this agreement with Debiopharm and support the development of its advanced USP1 inhibitor program. Following our successful collaborations with other clinical-stage companies, this latest agreement underscores the ability of Ubiquigent’s platform to cover all aspects of DUB drug discovery and development, including target validation, hit-to-lead, candidate selection, translational research and assay development to support clinical evaluation.”Ubiquigent CEO Jason Mundin said:“With several assets now reaching clinical stage, we look forward to further developing and expanding the DUB space in the coming years as more companies enter the space and new therapeutics enter the clinic.”

Bertrand Ducrey, CEO of Debiopharm, commented: “Ubiquigent's specialized drug discovery platform is uniquely positioned to support our USP1 inhibitor program in preparation for clinical development and enable the development of novel target engagement assays. Selective inhibition of USP1 to disrupt the DNA damage repair pathway is an exciting approach to cancer treatment.”

To learn more about Ubiquigent's DUB-focused drug discovery platform, visit:

Sources: